Clinical Trials Browser

liposomal doxorubicin × Gynecologic × 30 days × Clear all

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04092270 2026-04-17

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT07213804 2026-04-17

FRAmework-01

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

Phase 3 Recruiting

Ovarian Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT07504588 2026-04-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase 2 Not yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04516447 2026-04-07

MUIR

Phase 1 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06072781 2026-04-02

RAMP 301

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer